RxDoctor Payments Data

Patricia Naslund, MD

Neurology · Raleigh, NCNPI 1083643357

Payments from drug & device makers

$903in general payments, 2019–2025

Across 54 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$233
  • Novartis$164
  • Amgen$70
  • Biogen$62
  • Microtransponder, Inc.$35
  • Grifols USA, LLC$35
  • plus $304 from 15 others

What the payments were for

  • Food & beverage$89099%
  • Education$131%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$903 in reported general payments places this provider in the 45th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina

Medicare billing

Part B allowed, 2024
$1,448,059
Medicare patients
406
Services billed
34,120

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab13$664,824
PanzygaImmun Glob G(Igg)-Ifas/Glycine14$622,806
RebifInterferon Beta-1a/Albumin12$129,390
TecfideraDimethyl Fumarate11$103,893
Aimovig AutoinjectorErenumab-Aooe112$95,262
Emgality PenGalcanezumab-Gnlm70$63,586
Nurtec OdtRimegepant Sulfate61$61,853
UbrelvyUbrogepant25$31,012
QuliptaAtogepant14$25,306
TrileptalOxcarbazepine11$22,978
Emgality SyringeGalcanezumab-Gnlm16$22,946
NuedextaDextromethorphan Hbr/Quinidine13$19,267
Ajovy AutoinjectorFremanezumab-Vfrm23$16,270
LamictalLamotrigine13$14,083
KeppraLevetiracetam16$9,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$25$129,39012 claims
BiogenTecfidera$62$103,89311 claims
AbbVieUbrelvy, Qulipta$233$56,31839 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$14$1,27022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 566 neurology providers in North Carolina.

Other neurology in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →